Thanks DickyB
....for those that haven't got the time to go through - here's a quick snippet of what Lesile shared
https://youtu.be/S9F_bJwKkEw?si=MkFh3Dup3yVMZCYO
Leslie Chong (IMU)
"All of our platforms have at least more than complete response and then some of those patients are living three and half years out in remission"
"I really want all of us to be successful. We are all doing incredible novel work and I think also success builds on success. I hope for everyone on this panel to be successful because we need to get AUS biotech companies out there ...We're doing some revolutionary things here"
"Quite simple and complicated at the same time the clinical trial aspect encompasses phase 1, phase 2 phase 3 but now I think we are being smarter and faster, and unfortunately, FDA and other regulatory bodies do put constraints on what line of care we provide to patients - even if we think our products can work better in the front line - first instances/newly diagnosed which is great but we still have to abide by the ethics rules and regulatory bodies which say that you have to honour the SOC. It's actually unethical for any oncologist to treat any one/patients on what's considered an investigational drug/non approved drugs/still in clinical trials
...they have to exceed unfortunately the standard of care and the SOC happens to be the old main stay - the chemo/the radiation etc"
...."I like companies that have very experienced team have a record of having had experience with developing a certain kind of medicine ...you also want to see that sometimes phase 1 is great for safety rule outs but also this is when you get to look at how the drug works so when you see starts activity along with safety you've got something very special and I think companies owe it to themselves to develop those products and I'm fortunate at Imugene we have 4 products that have exceeded Phase 1, exceeded safety profile and I've seen efficacy as early as phase one"
....she then goes on to say because of the above (safety/efficacy) FDA and regulatory bodies are more open to fast tracking/orphan designation etc - to getting rapidly approved for market
I know that I don't contribute much to these threads but do appreciate those that genuinely do (be it + or -) ....let's collectively aim to get rid of this incessant fear mongering that's been rampant of late within these threads - yes it's a biotech and as investors we should be aware of how they generally play out - at the sane for those that are patient - there is a lot of upside should it come our way
Best Wishes to all things IMU
